Andere Kunden interessierten sich auch für
![Exploring the Frontiers of Innovation to Tackle Microbial Threats]( "Exploring the Frontiers of Innovation to Tackle Microbial Threats")
Exploring the Frontiers of Innovation to Tackle Microbial Threats76,99 €![A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases]( "A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases")
A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases55,99 €![The Infectious Etiology of Chronic Diseases]( "The Infectious Etiology of Chronic Diseases")
The Infectious Etiology of Chronic Diseases50,99 €![Facing the Reality of Drug-Resistant Tuberculosis in India]( "Facing the Reality of Drug-Resistant Tuberculosis in India")
Facing the Reality of Drug-Resistant Tuberculosis in India57,99 €![Accelerating the Development of Biomarkers for Drug Safety]( "Accelerating the Development of Biomarkers for Drug Safety")
Accelerating the Development of Biomarkers for Drug Safety32,99 €![Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis]( "Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis")
Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis49,99 €![Accelerating the Development of New Drugs and Diagnostics]( "Accelerating the Development of New Drugs and Diagnostics")
Accelerating the Development of New Drugs and Diagnostics44,99 €
Investment and innovation in drug research and development (R&D) for highly prevalent chronic diseases has stalled in recent decades, despite half of all Americans living with at least one chronic disease. As a result, prevalent chronic diseases are producing immense health care costs as well as preventable suffering and death. On February 22, March 2, and March 8, 2021, the National Academies of Sciences, Engineering, and Medicine, convened a workshop to discuss barriers to innovation in this space and examine strategies and incentives to support equitable, person-centered drug R&D for prevalent chronic diseases.